About Rheumatoid ArthritisThe disease is characterized by abnormal immune mechanisms that lead to joint inflammation and swelling with progressive destruction of joints. In addition to affecting the joints, RA can also affect connective tissue in the skin and organs of the body. 1
Current treatment of RA includes the use of non-steroidal anti-inflammatory drugs, oral disease-modifying antirheumatic drugs such as methotrexate, and injectable biological response modifiers that target pro-inflammatory cytokines implicated in the pathogenesis of RA, such as tumor necrosis factor.
About Lilly's Autoimmune Pipeline
Lilly has established its presence in autoimmunity in just a few short years through internal research and development and partnerships. Lilly currently has three potential new medicines in clinical development for a variety of autoimmune conditions, including tabalumab for RA and lupus, ixekizumab (an anti-IL-17 monoclonal antibody) for psoriasis and psoriatic arthritis, and baricitinib for RA, psoriasis and diabetic nephropathy.
Tabalumab and ixekizumab were discovered in Lilly's research laboratories.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in
, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at
This press release contains certain forward-looking statements about baricitinib and tabalumab as potential treatments for patients with rheumatoid arthritis and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that the product will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
Arthritis Foundation, What is Rheumatoid Arthritis,
October 25, 2012